Topic Listing for ISTA Pharmaceuticals

Acceleration Options Accrued Expenses
Acknowledgment Acsentient Agreement
Actual Future Payments Allowances Discounts Returns Rebates Chargebacks Adjustments Changes Capitalization Dissolution Liquidation Merger Asset Sale
Administration Plan Adopted Pursuant 906 Sarbanes-oxley Act 2002
Adoption 2006 Cash Bonus Plan Adoption 2007 Cash Bonus Plan
Adoption Cash Bonus Plan 2005 Aggregate Option Exercises 2004 Year-end Values
Aggregate Option Exercises 2005 Year-end Values Agreement
Agreement Loan Allergan Agreement
Alton Parkway Irvine California 92618 Amendment
Amendment Bromfenac License Agreement Amendment Termination
Amendment Termination Plan Amendments
Amendments Bromfenac License Agreement Annual Cash Bonus Plan
Annual Meeting Stockholders 2005 Annual Meeting Stockholders 2006
Annual Meeting Stockholders 2007 Annual Meeting Stockholders 2008
Annual Meeting Stockholders 2009 Api
Approve Adoption 2009 Employee Stock Purchase Plan Audit Committee Financial Expert
Audit Committee Report Audit Fees
Available Sale Securities Short Long Term Base Salary
Basis Presentation Batch Release Delivery
Beneficial Ownership Reporting Compliance Bepotastine
Bepotastine Nasal Bepotastine Nasal Collaboration Mitsubishi Tanabe
Bepotastine Nasal Collaboration Tanabe Bepreve Bepotastine Ophthalmic Solution
Black-scholes Value Ble Contents
Board Directors Board Directors Stockholders Ista Pharmaceuticals Inc
Board Meetings Committees Board Meetings Committees Directors Compensation
Bonus Borrowing Base Certificate
Broker Non-votes Capitalization
Caprogel Caprogel Aminocaproic Acid
Caprogel Collaboration Eastern Virginia Medical School Cash Bonus Plan
Cash Bonuses Cash Equivalents
Cautionary Regarding Forward-looking Statements Ceo Named Executive Officers Excluding Lauren Silvernail
Ceo Named Executive Officers Excluding Mrs Silvernail Certain Relationships Related Transactions
Certificate Secretary Certification
Certification Chief Executive Officer Certification Chief Financial Officer
Change Accounting Principles Change Control
Changes Internal Control Over Financial Reporting Changes Internal Control Over Financial Reporting Remediation Plans
Check Applicable Box Class Directors
Code Ethics Code Ethics Conduct
Collaborative Partners Terminate Fail Perform Duties Collaboration Agreements Commercial Update
Commitments Contingencies Committees
Common Preferred Stock Common Stock Warrants
Comparison Cumulative Total Return Compensation
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Committee Report Executive Compensation Determination Process
Compensation Directors Compensation Elements
Compensation Objectives Compensation Philosophy
Competition Compliance Certificate
Compliance Extensive Government Regulations Other Party Subject Expensive Compliance Extensive Government Regulations Subject Expensive Time Consuming
Comprehensive Income Comprehensive Income Loss
Comprehensive Loss Concentration Credit Risk
Concentration Ownership Contractual Board Rights Delay Prevent Change Conditions Disbursements
Conference Call Confidentiality Public Disclosure
Consent Independent Registered Public Accounting Firm Consent Ratification Spouse
Consolidated Financial Statements Ista Pharmaceuticals Inc Continuing Consolidation Distribution Network Concentration Customer Base Adversely
Contractual Obligations Controls Procedures
Conversion Notice Convertible Notes
Corporate Highlights Corporate Offices
Covenants Covered Employees
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies Estimates
Customers Distribution Default Credit Facility Required Immediately Repay Outstanding Borrowings
Default Indebtedness Required Immediately Repay Outstanding Borrowings Negatively Deferred Compensation
Deferred Compensation Plans Deferred Financing Fees
Definition Definitions
Depend Chief Executive Officer Vicente Anido Phd Other Dependence Key Personnel Operate Business Puts Risk Loss
Description Amended 2004 Plan Description Amendments
Developments Diabetic Retinopathy
Director Compensation Director Compensation Paid 2006
Director Compensation Paid 2007 Director Compensation Paid 2008
Director Independence Director Nominees
Directors Nominees Director Directors Officers Principal Stockholders Significant Voting Power Take
Directors Recommend Vote Directors Whose Terms Extend Beyond Annual Meeting
Dividend Policy Documents Incorporated Reference
Dry Eye Syndrome Ecabet Sodium
Effect Change Accounting Principle Condensed Consolidated Statements Operations Effective Date
Eligibility Eligibility Participation
Eligible Employees Employee Benefit Plan
Employee Stock Purchase Plan Employment Agreement Change Control Severance Lauren Silvernail
Employment Change Control Agreements End Operating Details
Entry Material Definitive Agreement Equipment Financing
Equity Compensation Plan Information Equity Compensation Plans
Equity Financing Estimates
Europe- Allergan Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Exchange Act 1934
Exclusive License Agreement Executive Employee Agreement
Executive Employment Agreements Executive Employment Agreements Each Vicente Anido Phd Marvin
Executive Officer Compensation Executive Officers Party Employment Agreement
Exhibits Existing Intellectual Property Rights Except Expressly Provided Below
Expansion Premises Explanatory
Exposed Product Liability Claims Insurance Against Not Available Face Intense Competition Rapid Technological Change Result Development
Facility Agreement Facility Agreement Redemption Outstanding Senior Subordinated Convertible Notes
Fail Properly Manage Anticipated Growth Business Suffer Fair Value Financial Instruments
Fair Value Measurements Family Relationships
Federal Income Tax Consequences Fees Billed Ernst Young Llp 2004 2003
Fees Billed Ernst Young Llp 2005 2004 Fees Billed Ernst Young Llp 2006 2005
Fees Billed Ernst Young Llp 2007 2006 Financial Covenants Borrower
Financial Outlook Financial Statements
Financial Statements Exhibits Forecasts Orders
Form 10-k Form 10-q
Form Ista Vice Presidents Form Lock-up Agreement
Form Senior Subordinated Convertible Former Name Address Changed Since Last Report
Forward Looking Statements Front Payment
Funding Date Shall Business Requested Borrowing Further Obligations Rights Parties
Future Sales Shares Common Stock Negatively Affect Price General
General Information General Matters
General Provisions Generated Minimal Revenue Product Sales Date History Net
Generic Manufacturers Litigation Regulatory Means Obtain Approval Versions Glaucoma
Government Regulation Grant Purchase Rights
Grant Security Interest Granting Awards
Guidance Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
History Net Losses Negative Cash Flow Need Raise Holders Common Stock
Human Resources Hyphema
Impact Accounting Tax Impairment Long-lived Assets
Income Taxes Increases Offering Size Shares
Indemnification Limitation Liability Indemnity
Index Index Consolidated Financial Statements
Index Exhibits Information
Information Contact Internal Bank Only
Introduction Inventories
Inventory Investigational Ophthalmic Therapy Allergic Conjunctivitis
Involvement Certain Legal Proceedings Ista
Ista Acquires Exclusive North American Rights Bepotastine Nasal Ista Pharmaceuticals 2006 Financial Results Reflect Strong Growth
Ista Pharmaceuticals Files Ind Phase Iib Trial Ecabet Ista Pharmaceuticals Inc
Ista Pharmaceuticals Increases Credit Facility Silicon Valley Bank Istalol
Istalol Timolol Istalol Xibrom Ecabet Sodium Collaborations Senju
Japan- Otsuka Lauren Silvernail
Lease Commitments License Fees Research Development Costs
Limitation Liability Limits Duties
Line Credit Liquidity Capital Resources
Lisa Grillone Phd List Indemnitees
Loan Modification Agreement Silicon Valley Bank Loan Security Agreement
Long-lived Assets Long-term Incentives
Management Report Internal Control Over Financial Reporting Managements Report Internal Control Over Financial Reporting
Mandatory Early Termination Manufacturing
Manufacturing Practices Market Registrants Common Equity Related Stockholder Matters Issuer
Marketing Sales Meetings
Membership Memorandum Otsuka Pharmaceuticals
Minimum Order Sizes Minutes
Miscellaneous Mitsubishi Tanabe Agreement
Multiple Api Combination Product Name Person Filing Proxy Statement Other Registrant
Name Registrant Specified Charter Net Loss Per Share
New Accounting Pronouncement New Accounting Pronouncements
New Accounting Standard Not Yet Adopted New Plan Benefits
Nominees Terms Expiring Annual Meeting Not Anticipate Declaring Cash Dividends Common Stock
Not Applicable Not Receive Maintain Regulatory Approvals Product Candidates Able
Not Receive Maintain Regulatory Approvals Products Product Candidates Not Voted Via Internet Telephone Fold Along Perforation
Notes Consolidated Financial Statements Number 000-31255
Ocular Inflammation Ocular Inflammation Eye Pain Photophobia
Offering Offering Periods
Officers Operating Details
Option Exercises Stock Vested 2006 Option Exercises Stock Vested 2007
Option Exercises Stock Vested 2008 Option Grants
Option Grants 2004 Option Grants 2005
Options Order Board Directors
Other Agreements Other Business Stockholder Proposals
Other Events Other Executive Officers
Other Matters Other Product Candidates Development Activities
Otsuka Agreement Outside Activities
Overview Part
Part Other Information Participation
Particular Covenants Events Default Patent Rights
Patents Proprietary Rights Payment 2004 Cash Bonuses
Payments Kirk Mcmullin Assuming 2006 Termination Payments Lauren Silvernail Assuming 2006 Termination
Payments Lauren Silvernail Assuming 2007 Termination Payments Marvin Garrett Assuming 2006 Termination
Payments Marvin Garrett Assuming 2007 Termination Payments Thomas Mitro Assuming 2006 Termination
Payments Thomas Mitro Assuming 2007 Termination Payments Timothy Mcnamara Assuming 2007 Termination
Payments Vicente Anido Phd Assuming 2006 Termination Payments Vicente Anido Phd Assuming 2007 Termination
Payroll Deductions Percent Greater Stockholders
Performance Incentive Plan Performance Share Agreements
Performance Shares Perquisite
Plan Administration Plan Distribution
Please Indicate Compliance Status Circling Yes Complies Column Power Attorney
Price Payment Terms Price Range Common Stock
Problems Contract Manufacturers Product Development Commercialization Efforts Delayed Problems Sole Source Suppliers Product Development Commercialization Efforts
Proceeds Fuel Istas Product Development Pipeline- Product Licensing Collaborations
Product Technical Transfer Product Testing
Products Not Gain Market Acceptance Business Suffer Because Products Pipeline
Products Product Pipeline Property Equipment
Proposed Public Offering Common Stock Proprietary Information Inventions
Public Accounting Firm Purchase Commitments
Purchase Stock Purpose Plan
Purposes Purposes Plan
Pursuant Internal Revenue Code 1986 Amended Quantitative Qualitative Disclosures Market Risk
Quarterly Results Fluctuate Significantly Fall Below Expectations Securities Quorum
Quorum Abstentions Broker Non-votes Ratification Appointment Independent Registered Public Accounting Firm
Reaffirming 2009 Financial Outlook Recall
Recent Accounting Pronouncements Recitals
Reclassifications Recommendation Board Directors
Record Date Principal Share Ownership Record Date Shares Outstanding
Records Reports Registrants Telephone Number
Registrants Telephone Number Including Area Code Registrants Telephone Number Including Area Code 949 788-6000
Registration Rights Agreement Registration Statement
Regulation Disclosure Regulatory
Related Party Transactions Relationship Between Parties
Renewal Option 15273 Premises Report Compensation Committee Executive
Report Independent Registered Public Accounting Firm Report Independent Registered Public Accounting Firm Internal Control
Reports Representations Warranties
Required Immediately Repay Outstanding Borrowings Financial Position Negatively Required Initiate Defend Against Legal Proceedings Related Intellectual
Research Development Research Development Costs
Responsibilities Restricted Cash
Restricted Shares Restricted Stock Awards
Results Results Operations
Results Operations Financial Condition Revenue Recognition
Review Approval Ratification Transactions Related Persons Revocability Proxies
Revolving Credit Facility Rising Cost Healthcare Related Pharmaceutical Product Pricing Lead
Risk Factors Risks Related Business
Risks Related Industry Role Compensation Committee
Role Compensation Consultant Determination Process Role Management Compensation Determination Process
Sales Products Continue Adversely Affected Continuing Consolidation Distribution Sample Notice Borrowing
Schedule Schedule Buyers
Schedule Exhibits Schedule Lenders
Schedules Seasonality
Securities Exchange Act 1934 Usc 1350 Securities Registered Pursuant Act
Security Agreement Segment Reporting
Selling Stockholders Senior Subordinated Convertible Notes
Senju Agreement Senju Pharmaceutical
Severance Benefits Shareholder Rights Plan
Shareholder Rights Plan Provisions Charter Documents Delaware Law Shares Available 2009 Espp
Shares Represented Proxy Voted Directed Stockholder Direction Given Shares Reserved Future Issuance
Short-term Investments Signature Page Follows
Signatures Signatures Following Page
Single Product Special Performance-based Awards
Specifics Compensation Determination Process Spreading Agent
Steroid Combination Product Stock
Stock Not Continue Traded Established Exchange Active Trading Stock Performance Graph
Stock Price Subject Significant Volatility Stock- Based Compensation
Stock-based Compensation Stockholder Communications Board Directors
Stockholder Rights Plan Provisions Charter Documents Delaware Law Stockholders Equity
Stockholders Sharing Same Last Name Address Strong Steroid Product
Subpoenas Subsequent Event
Substantial Future Sales Common Stock Public Market Depress Summary Federal Income Tax Consequences Amended 2004 Plan
Summary United States Federal Income Tax Consequences Amended Supplier
Suppliers Intellectual Property Rights Related Product Suppliers Manufacturers Subject Regulation Fda Other Agencies They
Supply Agreement Supply Concentration Risks
Supply Purchase Survival
T-pred Tobramycin Prednisolone Acetate Combination Product Table Cont Ents
Table Contents Tabular Disclosure Contractual Obligations
Tanabe Tanabe Agreement
Target Pay Mix Compensation Elements Tax Withholding
Taxes Duties Fees Term Termination
Termination Termination Employment
Termination Employment Change-in-control Agreements Third-party Manufacturers Suppliers Not Meet Commitments Find Substitute
Third-party Reimbursement Not Available Products Accepted Market Third-party Reimbursement Not Available Satisfactory Levels Products Accepted
Title Class Tobramycin Prednisolone Acetate Combination Product
Trading Stock Over Last Been Limited Investors Not Transactions Related Persons
Unable Execute Strategic Plan Material Adverse Impact Business Unable Obtain Materials Sole Source Suppliers Timely Manner
Unable Sufficiently Develop Sales Marketing Distribution Capabilities Enter Undersigned Represents Warrants True Complete Correct Information Borrowing
United States Unregistered Sale Equity Securities
Unstable Market Conditions Service Adverse Consequences Business Updating 2009 Financial Outlook
Visionex Vitrase
Vitrase Ovine Hyaluronidase Vitrase Vitragan Ovine Hyaluronidase
Vitreous Hemorrhage Vote Required
Voting Solicitation Warrants
Whereas Withdrawal
Xhibit Xibrom
Xibrom Bromfenac Xibrom Bromfenac 009 Once-daily
Xibrom Bromfenac 009 Twice-daily Xibrom Bromfenac Lower Concentration
Xibrom Istalol Bepotastine Ecabet Sodium Latanoprost Iganidipine Collaborations Xibrom Istalol Bepreve Ecabet Sodium Latanoprost Iganidipine Collaborations
Xibrom Istalol Bepreve Ecabet Sodium Prostaglandins Iganidipine Collaborations Xibrom Istas Product Launched Market
Year-end Option Values 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki